Workflow
CVTE Robot Products Make Collective Debut at Canton Fair
Globenewswire· 2025-11-03 14:35
产品发布与市场关注度 - 公司在第138届中国进出口商品交易会(广交会)上推出了新的机器人产品系列,其中MAXHUB A3系列智能柔性机械臂为首次公开亮相 [1] - 公司的商用清洁机器人在展会期间获得了全球访客的广泛关注 [4] 国际化商业进展 - 公司的商用清洁机器人已与亚太地区(包括日本、韩国、新加坡)以及欧洲主要市场(包括德国、英国、法国、意大利、荷兰、瑞典、波兰)的客户建立合作伙伴关系 [3] - 该机器人解决方案已在多个海外地点开始初步部署 [3]
Sampo plc’s share buybacks 31 October 2025
Globenewswire· 2025-11-03 14:30
股份回购交易详情 - 公司于2025年10月31日通过四个交易场所(AQEU、CEUX、TQEX、XHEL)回购了总计295,568股A股股份 [1] - 本次回购的股份数量分别为:AQEU 7,240股、CEUX 111,363股、TQEX 36,894股、XHEL 140,071股 [1] - 所有回购交易的每日加权平均价格均为每股9.72欧元 [1] 股份回购计划背景 - 公司股份回购计划于2025年8月7日启动,最高回购金额为2亿欧元 [1] - 该计划基于2025年4月23日年度股东大会的授权,并符合欧盟市场滥用法规 [1] 累计持股情况 - 在本次披露的交易完成后,公司总计持有20,484,833股自身A股股份 [2] - 公司持有的自身股份占总股本的比例为0.76% [2]
Renault Group and Geely strengthen their cooperation with the completion of a partnership in Brazil
Globenewswire· 2025-11-03 14:30
合作核心内容 - 雷诺集团与吉利控股集团已签署最终协议,将战略合作扩展至巴西市场,涉及零排放和低排放汽车的生产与销售 [1] - 吉利正式收购雷诺巴西公司26.4%的股权,雷诺集团仍为控股股东并继续合并该实体报表 [2] - 此次合作旨在加速双方在巴西这一关键市场的发展,巴西占2025年上半年拉丁美洲汽车注册量的40%以上 [4] 生产与工业安排 - 吉利和雷诺品牌的汽车将在巴西圣若泽杜斯皮尼艾斯的Ayrton Senna工厂共同生产,以提高产量并增强该先进工业综合体的竞争力 [3] - 吉利将获得雷诺巴西公司工业和商业资源的使用权,以加速其在巴西市场的扩张 [2] - 雷诺将利用吉利的GEA新能源架构,为巴西市场扩展其零排放和低排放汽车产品线 [3] 商业与销售策略 - 雷诺巴西公司将在巴西分销吉利汽车的零排放和低排放汽车产品组合,为销售、金融和服务开辟新的增长机会 [4] - 吉利EX5电动SUV已通过雷诺网络运营的专属品牌经销商在巴西市场销售 [2] 合作背景与战略意义 - 此次巴西合作是双方国际战略的决定性一步,建立在工业卓越和技术领导力的基础上 [5] - 合作将使双方在快速变化的汽车市场中更具竞争力、创新性和响应速度 [5] - 双方此前已建立多个全球合作项目,包括共同投资雷诺韩国公司以及成立Horse Powertrain [5][11]
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Globenewswire· 2025-11-03 14:00
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1These positive results follow the r ...
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Globenewswire· 2025-11-03 14:00
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of Nephrology (ASN) Kidney Week 2 ...
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
Globenewswire· 2025-11-03 14:00
Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance. Founded in 2018 by Dr. Paul Jahnke and Dr. Fe ...
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
Globenewswire· 2025-11-03 14:00
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a poster at the ...
Corbion reports the progress of its share buyback program 27 October – 31 October 2025
Globenewswire· 2025-11-03 14:00
Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 27 October up to and including 31 October 2025 a total of 102.003 shares were repurchased at an average price of €17.6450 for a total amount of €1,799,838.05 To date, the total consideration for shares repurchased amounts to 420,203 shares representing 72.40% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of ...
Ensurge and Corning announce collaboration to advance solid-state microbattery technology
Globenewswire· 2025-11-03 13:01
合作概述 - Ensurge与康宁公司宣布达成一系列协议 共同开发Ensurge的超高性能固态微型电池 [1] - 协议为两家公司整合康宁的Ribbon Ceramic材料及工艺技术与Ensurge成熟的固态微型电池架构建立了框架 [2] - 合作旨在推出超高能量密度的产品线扩展 以商业化用于消费电子、医疗、工业和国防领域的大批量应用的电池 [2] 合作战略意义 - 合作代表了Ensurge的一个重要战略里程碑 [3] - 将康宁的材料科学领导力应用于Ensurge的固态微型电池平台 为下一代智能设备的变革性进步奠定基础 [3] - 两家公司共同致力于卓越的创新和制造 [3] Ensurge公司背景 - 公司是固态微型电池技术领域的全球领导者 总部位于加利福尼亚州圣何塞 [1][4] - 公司拥有世界一流的专家团队 开创了在高精度卷对卷生产线上生产的薄膜电池 [4] - 其创新技术为消费电子、医疗和工业市场中受外形尺寸限制的应用带来了新的可能性 [4] - 公司与全球领先客户合作 加速其人工智能驱动产品上市 并在奥斯陆证券交易所上市 [4] 康宁公司背景 - 康宁公司是材料科学领域的世界领先创新者之一 拥有170年的历史 [5] - 公司在玻璃科学、陶瓷科学和光学物理方面拥有无与伦比的专长 并具备深厚的制造和工程能力 [5] - 公司通过持续研发投资 材料与工艺创新的独特组合 以及与行业全球领先客户的深度信任关系取得成功 [5] - 其市场涵盖光通信、移动消费电子、显示、汽车、太阳能、半导体和生命科学 [5]
Ensurge Micropower ASA – Joint development and investment agreements with Corning Incorporated to advance solid-state microbattery technology
Globenewswire· 2025-11-03 13:00
Oslo, Norway, 3 November 2025 Ensurge Micropower ASA ("Ensurge" or the "Company") today announces that the Company has entered into a set of agreements with Corning Incorporated (“Corning”), one of the world’s leading innovators in glass, ceramics, and materials science, to jointly develop ultra-high performance solid-state microbatteries based on Ensurge’s platform. Ensurge and Corning have entered into a joint development agreement to establish a framework and joint development program for the two compan ...